MedPath

Minocycline Hydrochloride

These highlights do not include all the information needed to use MINOCYCLINE HYDROCHLORIDE EXTENDED RELEASE TABLETS safely and effectively. See full prescribing information for MINOCYCLINE HYDROCHLORIDE EXTENDED RELEASE TABLETS. MINOCYCLINE HYDROCHLORIDE extended-release tablets, for oral use Initial U.S. Approval: 1971

Approved
Approval ID

6e0efd1a-5a09-4030-8fe2-f98334cdeb0e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 20, 2025

Manufacturers
FDA

Bryant Ranch Prepack

DUNS: 171714327

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Minocycline Hydrochloride

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code63629-9208
Application NumberANDA204453
Product Classification
M
Marketing Category
C73584
G
Generic Name
Minocycline Hydrochloride
Product Specifications
Route of AdministrationORAL
Effective DateAugust 20, 2025
FDA Product Classification

INGREDIENTS (12)

HYPROMELLOSE 2208 (4000 MPA.S)Inactive
Code: 39J80LT57T
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
TRIACETINInactive
Code: XHX3C3X673
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
POLYETHYLENE GLYCOL 3350Inactive
Code: G2M7P15E5P
Classification: IACT
ALUMINUM OXIDEInactive
Code: LMI26O6933
Classification: IACT
FD&C BLUE NO. 1Inactive
Code: H3R47K3TBD
Classification: IACT
MINOCYCLINE HYDROCHLORIDEActive
Quantity: 105 mg in 1 1
Code: 0020414E5U
Classification: ACTIM
HYPROMELLOSE 2910 (50 MPA.S)Inactive
Code: 1IVH67816N
Classification: IACT
D&C RED NO. 27Inactive
Code: 2LRS185U6K
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 8/20/2025

Minocycline HCL 105 mg ER tab#30

Label

Indications & Usage Section

LOINC: 34067-9Updated: 8/20/2025

1 INDICATIONS & USAGE

1.1 Indication

Minocycline hydrochloride extended-release tablets is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

1.2 Limitations of Use

Minocycline hydrochloride extended-release tablets did not demonstrate any effect on non-inflammatory acne lesions. Safety of Minocycline hydrochloride extended-release tablets has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections [see Clinical Studies (14)].
To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, Minocycline hydrochloride extended-release tablets should be used only as indicated [see Warnings and Precautions (5.11)].

Description Section

LOINC: 34089-3Updated: 9/20/2019

11 DESCRIPTION

Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4α,4aα,5aα, 12aα)] - 4,7 – Bis (dimethylamino) -1,4,4a,5,5a,6,11,12a - octahydro-3,10,12,12a -tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride.
The structural formula is represented below:

mino-struc

C23H27N3O7•HCl M. W. 493.95

Minocycline hydrochloride extended-release tablets, USP for oral administration contain minocycline hydrochloride USP equivalent to 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, and 135 mg of minocycline. In addition, 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, and 135 mg tablets contain the following inactive ingredients: lactose monohydrate, hypromellose type 2910, hypromellose type 2208, colloidal silicon dioxide, magnesium stearate, titanium dioxide and triacetin.

The 45 mg tablets also contain iron oxide black.

The 65 mg tablets also contain FD&C blue #1/brilliant blue FCF aluminium lake,

polyethylene glycol 3350, FD&C blue #2/indigo carmine aluminum lake and D&C yellow #10 aluminum lake.

The 55 mg tablets also contain macrogol, FD&C RED #40.

The 80 mg tablets also contain macrogol, FD&C blue #2, FD&C red #40, FD&C yellow

#6.

The 90 mg tablets also contain iron oxide yellow and polyethylene glycol 3350.

The 105 mg tablets also D&C red #27, macrogol, FD&C blue #1.

The 115 mg tablets also contain D&C yellow #10 aluminum lake, FD&C blue #1/brilliant blue FCF aluminium lake and FD&C blue #2/indigo carmine aluminum lake.

The 135 mg tablets also contain polyethylene glycol 3350 and iron oxide red.

The USP Dissolution Test is pending

How Supplied Section

LOINC: 34069-5Updated: 8/20/2025

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied
Minocycline hydrochloride extended-release tablets, USP are supplied as aqueous film coated tablets containing Minocycline hydrochloride equivalent to 105 mg minocycline, are supplied as follows.

The 105 mg extended release tablets are Purple colored capsule shaped film coated tablets, debossed with "105'' on one side, plain on other side.Each tablet contains Minocycline hydrochloride equivalent to 105 mg minocycline, supplied as follows:

NDC 63629-9208-1

Bottle of 30

16.2 Storage

Store at 20˚ to 25˚C (68˚ to 77˚ F) [See USP Controlled Room Temperature].

16.3 Handling

Keep out of reach of children.
Protect from light, moisture, and excessive heat.
Dispense in tight, light-resistant container with child-resistant closure.

Repackaged/Relabeled by:

Bryant Ranch Prepack, Inc.

Burbank, CA 91504

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Minocycline Hydrochloride - FDA Drug Approval Details